ONCOPRO

Blood biomarkers hold a significant promise for improving the diagnosis and the monitoring of treatment responses across multiple cancer types. However, their widespread adoption in clinical practice requires rigorous testing to ensure their reliability, validity, and utility across different cancer types.

​

ONCOPRO is a French, prospective, observational, monocentric study with longitudinal follow-up, in which 420 patients with 16 different types of cancer are included. Blood samples will be taken at diagnostic and during their treatment follow-up to evaluate plasma concentrations of hPG80.

​

Study in partnership with the Hospice Civils de Lyon (France).

​​

ONCOPRO is registered at ClinicalTrials.gov (NCT03787056)

​

Current Status: Follow-up